Embracing Personalization in Biopharma Patient Support Programs
Fierce Pharma
APRIL 18, 2023
Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48
Biopharma Patients Pharma 
Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence
MedCity News
NOVEMBER 10, 2024
The post Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence appeared first on MedCity News.
Patients 
311
311 Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Advancing Patient & Planet Health Through Proper Healthcare Waste Management
MedCity News
APRIL 24, 2025
By prioritizing sustainability-minded and compliant waste management in the workplace, healthcare leaders can advance patient and employee well-being, as well as environmental and fiscally responsible programs. The post Advancing Patient & Planet Health Through Proper Healthcare Waste Management appeared first on MedCity News.
Management 191
191 
Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds
MedCity News
JANUARY 31, 2025
Vertex Pharmaceuticals Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The post Vertex Pharmas Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds appeared first on MedCity News.
FDA 276
276 
Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients
MedCity News
JULY 18, 2024
Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). The post Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients appeared first on MedCity News.
Pharma 278
278 
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
MedCity News
MARCH 17, 2025
AstraZenecas EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases. EsoBiotecs allogeneic cell therapies are made by the in vivo reprogramming of a patients immune cells.
Pharma 278
278 
Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales
MedCity News
MARCH 5, 2025
Wegovy will ship directly to eligible patients through NovoCare, an online pharmacy established by Novo Nordisk. The products price matches a recent price cut for Zepbound offered by Eli Lilly through its own direct-to-patient online platform.
Sales 232
232 
How Tech Changes to Clinical Trials Help Both Patients and Biopharma Firms
MedCity News
OCTOBER 27, 2023
Technology is transforming how clinical trials are run. A panel during MedCity News’ INVEST Digital Health conference discussed the tech trends shaping the design and execution of drug studies.
Biopharma 317
317 
Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency
MedCity News
AUGUST 12, 2024
FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. The post Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency appeared first on MedCity News.
FDA 306
306 
Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD
MedCity News
JUNE 27, 2024
Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. The post Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD appeared first on MedCity News.
Pharma 290
290 
How Data and AI Help Pharma Sales Teams Better Market Precision Genetic Drugs
MedCity News
MARCH 18, 2024
As GenAI and other technologies advance the speed of development and the precision of drugs, pharma commercial teams need to make sure they are harvesting the right data with the right AI tools in order to ultimately reach the right patients.
Pharma 305
305 
Top 5 Strategic Focus Areas for Global Pharma Marketers in 2024
MedCity News
FEBRUARY 14, 2024
2024 presents an exciting yet challenging landscape for global pharma marketers.
Marketing 288
288 
A VC’s take on the $1.3 billion acquisition of CinCor Pharma by AstraZeneca
MedCity News
JANUARY 10, 2023
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.
Pharma 296
296 
Sanofi’s FDA Nod in Hemophilia Gives Patients More Convenience, Brings Roche New Competition
MedCity News
FEBRUARY 23, 2023
FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.
Competition 279
279 
Should Patients Have the Right to Own Their Clinical Trial Data?
MedCity News
DECEMBER 28, 2022
It fits in amongst the goal of running nimble and patient-centered studies. But, without legislation, it’s doubtful that pharma companies will give up ownership of participant data out of sheer goodwill. Putting data into the hands of participants is an important step in changing the traditional clinical trial paradigm.
Patients 264
264 
The Direct-to-Patient Platform: Transforming the Patient Journey for Better Outcomes
Fierce Pharma
OCTOBER 3, 2024
Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)
Patients 130
130 
With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs
MedCity News
SEPTEMBER 4, 2024
Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players.
Patients 321
321 
How Digital Technologies are Solving Pain Points for Pharma Companies
MedCity News
OCTOBER 29, 2023
A panel at the MedCity News INVEST conference in Dallas discussed how new tech platforms help speed up the process of recruiting patients and running clinical trials. AI technologies have a role in the life sciences that goes beyond drug discovery.
Recruitment 338
338 
Polypharmacy is a Health Killer: Personalized Medication Management is the Answer
MedCity News
NOVEMBER 20, 2024
We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcare providers, and personalized medicine practices such as pharmacogenomics.
Management 297
297 
Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug
MedCity News
APRIL 17, 2025
The first Phase 3 results for Eli Lillys daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes. The pharmaceutical giant plans global regulatory submissions starting at the end of this year.
Medicine 235
235 
GSK Wagers $80M on a Tech Platform and Parkinson’s Drug from Flagship-Founded Vesalius
MedCity News
NOVEMBER 17, 2024
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.
Patients 306
306 
GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH
MedCity News
DECEMBER 9, 2024
Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex.
FDA 290
290 
FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery
MedCity News
APRIL 23, 2024
ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The post FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery appeared first on MedCity News. The novel immunotherapy works by sparking activity from three types of immune cells.
FDA 321
321 
FDA Approves First Drug for Treating Agitation in Alzheimer’s Patients
MedCity News
MAY 11, 2023
Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
FDA 312
312 
Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative
MedCity News
SEPTEMBER 5, 2024
Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. The post Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative appeared first on MedCity News.
Patients 289
289 
Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial
MedCity News
APRIL 14, 2025
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
Safety 237
237 
The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients
MedCity News
JUNE 21, 2024
The post The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients appeared first on MedCity News. Underrepresentation of racial and ethnic groups and other historically disenfranchised populations in clinical trials continues to be a major challenge. Medical Affairs can help identify solutions.
Medical 298
298 
Fierce Pharma Asia—Enhertu's encore; Akeso's showstopper; GenScript and Legend's US scrutiny
Fierce Pharma
JUNE 6, 2024
AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. lawmakers.
Biopharma 169
169 
Rising Investment in Patient Support Drives a Greater Biopharma Focus on Measurement
Fierce Pharma
FEBRUARY 27, 2024
Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support. A seismic shift has occurred in the healthcare landscape.
Biopharma 170
170 
Why One Expert Thinks the Medicare Drug Price Negotiation Program Is Here to Stay
MedCity News
OCTOBER 10, 2023
Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma players file lawsuits. among pretty much everyone who isn’t a pharma company, she said during a session at Engage at HLTH. Her reasoning?
Pharma 306
306 
Putting patients at the center of RWD collection processes [Sponsored]
MedCity News
AUGUST 30, 2022
the European Union and other countries amid ongoing efforts to encourage patients who want to share their data. In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S.,
Patients 279
279 
CinCor Hypertension Drug Flunks Study, But the Biotech Still Sees a Phase 3 Path
MedCity News
NOVEMBER 28, 2022
Cincor Pharma drug baxdrostat failed its Phase 2 test, falling short of the goal of reducing blood pressure in patients with uncontrolled hypertension. But results in a subgroup of patients showed double-digit declines, which the company said could inform the design of a Phase 3 clinical trial.
Pharma 326
326 
Pharma Just Increased the Price of Hundreds of Drugs. PBMs are Minimizing the Impact for Health Plans, Employers and Patients
MedCity News
JANUARY 28, 2024
While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.
Competition 325
325 
Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs
MedCity News
APRIL 8, 2024
The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products. The post Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs appeared first on MedCity News.
FDA 317
317 
FDA approval of AstraZeneca drug is first for a new group of breast cancer patients
MedCity News
AUGUST 5, 2022
Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused therapy the first targeted treatment for this new category of breast cancer patients.
FDA 299
299 
FDA turns down Acadia Pharma drug for Alzheimer’s psychosis; new trial needed
MedCity News
AUGUST 7, 2022
Acadia Pharmaceuticals drug Nuplazid failed to win FDA approval for the treatment of psychosis in Alzheimer’s disease patients. The regulator said that the data submitted were not from an adequate and well-controlled study and the company must run another clinical trial.
FDA 299
299 
Theseus Pharma Lays Off Staff, Explores Options Months After Toxicity Scuttles Lead Drug
MedCity News
NOVEMBER 14, 2023
Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”
Leads 290
290 
Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think
MedCity News
JULY 10, 2024
The post Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think appeared first on MedCity News. Amylyx plans to advance this GLP-1 antagonist into Phase 3 testing for post-bariatric hypoglycemia, a rare condition in which blood sugar levels drop precipitously.
Patients 293
293 
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
MedCity News
FEBRUARY 2, 2025
As the pharmaceutical landscape evolves, small-molecule CDMOs will be essential in balancing supply and demand, driving innovation, and improving patient outcomes. They must continue embracing innovation and strategic agility to survive and thrive in this complex environment.
Pharmaceutical 262
262 
Here’s how biopharma can better support patients while they’re searching for care
Fierce Pharma
SEPTEMBER 27, 2024
Patients with rare or complex diseases often struggle to find specialists who meet their specific condition and individual needs. Patients with rare or complex diseases struggle to find specialists who fit their unique needs, delaying crucial care. Digital tools can help.
Biopharma 130
130 
Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds
MedCity News
NOVEMBER 20, 2022
While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.
Patients 289
289 
Beyond The Traditional KOL: 3 Reasons Pharma Should Tap Nurses as Change Agents
MedCity News
JANUARY 30, 2024
As key opinion leaders (KOLs), nurses can provide insights on unmet clinical needs, identify gaps in treatment options, and contribute to the development of better and more patient-centric solutions. Here are three core reasons why pharmaceutical companies should tap the power of nurses.
Pharma 290
290 
Access solutions: the missing link that prevents biopharma innovation from reaching patients
pharmaphorum
DECEMBER 18, 2022
Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.
Biopharma 98
98 
Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug
MedCity News
MARCH 27, 2025
Soleno Therapeutics Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare disease, a leading cause of childhood obesity.
Leads 227
227 
Let's personalize your content